Skip to main content
Equibles
GPCR logo

GPCR · Structure Therapeutics Inc.

Track GPCR — free

Use GPCR with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about GPCR

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$47.38 -1.84 (-3.74%)
Rebalance outlook locked
Market Cap
$3.51B
Shares
71.31M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$49.22 Open$49.61 Day$48.50–49.81 52W close$19.00–93.79 Avg vol 30d599K Short int6.1M · 8.5% float · 10.4d Short vol59% Last earningsNov 13, 2024 DataFeb 2023–Aug 2026 Filing10-Q · Aug 6

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 6, 2026

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 14.5 · calm Equity put/call 0.39
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −9%
below
Price vs 50-day avg −3%
below
RSI (14) 44
neutral
MACD trend Negative
52-week position 40%
mid-range
Momentum
relative strength
Very Weak
1-month return −1%
trailing
6-month return −15%
trailing
YTD return −29%
this year
Relative strength −29%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $51 › 200d $54 — 200d above 50d
Institutional flow Distributing
-3% holders QoQ · +29 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
8.53% of float · ▲ +0.5% MoM · 10.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
194 holders — near 3-yr high, broad support
Squeeze score 63
elevated · 0–100
Fundamentals
Weak
EPS growth −3%
Y/Y
Free cash flow $-225.8M
Balance sheet $799.6M
net cash
Quant / Vol
risk profile
Very High
Volatility 119%
annualized · 1-yr
Max drawdown −62%
past year
ATR 4.8%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
2 · 4 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−9% Bearish
Price vs 50-day avg
−3% Neutral
RSI (14)
44 Neutral
MACD trend
Negative Bearish
52-week position
40% Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $51 › 200d $54 — 200d above 50d
Institutional flow Distributing
-3% holders QoQ · +29 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
8.53% of float · ▲ +0.5% MoM · 10.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
194 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $19 Now $49 · 40% Range high $94
vs 200-day avg -9% vs 50-day avg -3%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
placebo-adjusted mean weight loss (aleniglipron 120 mg dose at 36 weeks, Phase 2b ACCESS study) 11.3% Q4 FY2025 —
placebo-adjusted mean weight loss (aleniglipron 240 mg dose at 36 weeks, ACCESS II study) 15.3% Q4 FY2025 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
GPCR
Structure Therapeutics Inc.
this stock
$3.51B -29.2% — — 8.5%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $138.72B +20.8% +46.2% 31.9 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.27B +4.6% +20.8% 19.6 2.3%
ARGX
Argenx SE
 $65.12B +25.9% — — 1.9%
CSLLY
Csl Ltd
 $59.92B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
194
% held
95.5%
Net QoQ
+488.6K sh
Top holder
FMR LLC
Held Float
View
Held by Funds
Fund positions
150
View
Short & Settlement
Short Interest Rising
Shares short
6.1M
Days to cover
10.4d
Change
+30.0K sh
View
Short Volume
Short vol %
59%
As of
Aug 28, 2026
Short Total
View
Fails to Deliver
FTD shares
495
Value
$22.8K
As of
Jul 17, 2026
View
Off-Exchange
Off-exchange %
44.1%
Week of
Jul 20, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Sell
Member
Thomas R Carper
Amount
$1.0K–$15.0K
Traded
Oct 4, 2023
View
Financials
Financials
Net income (FY)
$-141.2M
EPS diluted
$-0.80
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 6, 2026
This year
13
View
Proposed Sales
Value
$1.7M
Shares
35.5K
Filed
Jun 25, 2026
View
Exempt Offerings
Offering
$7.0M
Filed
Jan 10, 2022
View
Earnings & Events
Earnings Calls
Last call
Jun 9, 2026
View
Investor Relations
Latest news
Structure Therapeutics Reports Se…
Published
Aug 6, 2026
View

Performance

5D 20D 120D MTD YTD
GPCR -2.6% -0.5% -14.7% +2.5% -29.2%
SPY +1.1% +4.0% +14.7% +3.2% +13.1%
vs SPY -3.7% -4.5% -29.4% -0.8% -42.3%
Key facts CIK 1888886 CUSIP 86366E106 13F (30d) 171 filings 170 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)